As a Biologic Coordinator, one of the most common questions I hear from patients is:

“What is a biosimilar? and is it as good as my current medication?”
It’s a great question. Whether you’re being treated for a chronic condition like psoriasis, Crohn’s disease, rheumatoid arthritis, or cancer, understanding and knowing your options regarding biosimilars, can help you feel more confident and informed in your care. Yet biosimilars are becoming an increasingly important part of how we treat complex disease, and they could have a big impact on your health, your pockets, and access to care. As a Biologic Coordinator, I work closely with patients to obtain overage, education, and access.

Who are Biosimilars?
Biosimilars are lower-cost versions of biologics, basically copycats. Thy are administered the same way, provide the same treatment and benefits, and have the same strength, safety, and efficacy as their original biologic, also known as the reference medication. They can only be manufactured once a reference medication is no longer patent protected. A few name brands such as Humira and Stelara who now have biosimilars. Why not call them generic?

Humira: Amjevita, Cyltezo, Hadlima, Hyrimoz, Idacio, Simlandi, Yuflyma, Hulio, Yusimry, Abrilada.

Stelara: Wezlana, Selarsdi, Pyzchiva, Yesintek, Otylfi, Imuldosa, Steqeyma.

What’s in It for my patients?
Lower Costs
They usually come with reduced pricing compared to brand-name biologics. This means patient co-pays should be lower, and insurance plans are more likely to approve them. I see more biosimilars on formulary and being first line over biologics. Most biosimilars have the same options as biologics such as a copay savings card, nurse guide, injection training, patient assistance options, and more.

More Access to Treatment
Most insurance/pharmacy benefit managers prefer biosimilars medications. Now when you send in a prescription, they are giving patients a biosimilar version. The prior authorization seems to be getting approved much faster.

Same Safety and Effectiveness
Biosimilars go through a rigorous approval process by the FDA. They must prove they work just as well, with no meaningful clinical differences from the original biologic. In fact, most doctors I work with are now very comfortable recommending them—especially for patients just starting therapy. Some are interchangeable, meaning it can be substituted for the original biologic at the pharmacy, without your doctor needing to change the prescription. They supposedly work the same.

Moving Forward
Don’t be afraid to ask questions—we’re here to help.

As a Biologic Coordinator, I’m here to help patients understand the option, understand the insurance process, and make sure they receive the medication in a timely manner. I will make sure their transition to a biosimilar is seamless and safe. I’ve watched biosimilars change lives not just medically, but financially and emotionally. For patients who once struggled to afford or access therapy, biosimilars have opened new doors. That’s why I believe patients should care.

If your patient is unsure about what’s right for them, offer to talk through options. Work together to find the safest, most affordable option for their care.

Final Thought: 
Pharma companies say it’s an opportunity to receive the same life-changing care with fewer barriers in your patients’ way. Only if life was that easy and simple! But with the right support team by their side, the best decision will be chosen.